Follow live updates and real-time coverage of NBA Finals game 7 as the Thunder and Pacers face off for the championship. Tyrese Haliburton was hurt in the first quarter.

Foresight Diagnostics Logo (PRNewsfoto/Foresight Diagnostics, Inc.) This collaboration combines Foresight's innovative MRD detection technology with QIAGEN's global leadership in molecular ...

This press release contains forward-looking statements, including, but not limited to our statements related to the potential power of Veracyte’s whole-genome approach, which will now enable us to ...

MRD detection is the future — allowing us to monitor patients in real-time. The data is strong and we're excited that our approach can now be incorporated into future studies." ...

In an interview with CURE®, Flowers, who works in the Department of Lymphoma — Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, delved into the ...

As sensitivity level 10-6, MRD-negative patients experienced superior PFS, compared with MRD-positive patients in both treatment groups. Further, the 54-month PFS rates for MRD-negative patients ...

1 Munshi NC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 Dec 8;4(23):5988-5999. 2 ...

The positive predictive value (PPV) of MRD detection was 100% and 90.9% at the landmark and longitudinal time points, respectively, indicating a high risk of recurrence for patients with positive MRD.

Don't wait for MRD negativity if someone's having toxicities but the absence of that, I do think it's reasonable, based on the data from the master study showing that in the absence of 2 or more ...

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...

Per a BIS Research report, the MRD testing market was valued at $1.67 billion in 2023 and is expected to reach $6.67 billion by 2033, at a CAGR of 14.81%.

Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The ...